SCHEMBL14033902

SCHEMBL14033902

FC(F)(F)c1ccc(C(Cl)c2ccc(Br)cn2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.39
S1PR3 Q99500 7/20 0.35
S1PR4 O95977 3/20 0.35
THRB P10828 1/20 0.34
ABL1 P00519 1/20 0.34
SRC P12931 1/20 0.34
MAOB P27338 1/20 0.33
CYP19A1 P11511 2/20 0.32
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32
KCNE1 P15382 1/20 0.32
KCNQ1 P51787 1/20 0.32
AHR P35869 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
S1PR1 P21453 1/20 0.31
PDE2A O00408 1/20 0.31
S1PR2 O95136 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033813 1.00 TRPV1 (0.39) TRPV1S1PR3S1PR4THRBABL1
SCHEMBL14033202 0.81 TRPV1 (0.39) TRPV1S1PR3S1PR4THRBMAOB
SCHEMBL14033200 0.81 NPC1 (0.36) S1PR3S1PR4ABL1PDE2A
SCHEMBL14034090 0.81 NPC1 (0.36) S1PR3S1PR4ABL1PDE2A
SCHEMBL14033306 0.80 S1PR3 (0.43) S1PR3S1PR4S1PR1S1PR2
SCHEMBL14033593 0.80 S1PR3 (0.43) S1PR3S1PR4S1PR1S1PR2
SCHEMBL14033932 0.78 S1PR3 (0.51) S1PR3S1PR4S1PR2
SCHEMBL14033749 0.78 S1PR3 (0.51) S1PR3S1PR4S1PR2
SCHEMBL6075652 0.73 CES2 (0.45) CYP19A1AHRCES2CES1PDE2A
SCHEMBL4602819 0.72 S1PR3 (0.43) S1PR3S1PR4S1PR1S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed